BING Z CARTER to Humans
This is a "connection" page, showing publications BING Z CARTER has written about Humans.
Connection Strength
0.385
-
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023 09 21; 142(12):1056-1070.
Score: 0.018
-
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica. 2023 09 01; 108(9):2513-2519.
Score: 0.017
-
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther. 2022 06 01; 21(6):879-889.
Score: 0.016
-
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022 01 01; 107(1):58-76.
Score: 0.016
-
Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood. 2021 10 28; 138(17):1637-1641.
Score: 0.015
-
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Mol Cancer Ther. 2020 08; 19(8):1636-1648.
Score: 0.014
-
An ARC-Regulated IL1?/Cox-2/PGE2/?-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Res. 2019 03 15; 79(6):1165-1177.
Score: 0.013
-
Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429.
Score: 0.012
-
Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144.
Score: 0.011
-
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016 09 07; 8(355):355ra117.
Score: 0.011
-
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1? signaling network. Oncotarget. 2016 Apr 12; 7(15):20054-67.
Score: 0.010
-
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015 Oct 13; 6(31):30487-99.
Score: 0.010
-
Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol. 2014 Nov; 167(3):376-84.
Score: 0.009
-
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014 Feb; 106(2):djt440.
Score: 0.009
-
XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res. 2013 Aug; 37(8):974-9.
Score: 0.009
-
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80.
Score: 0.008
-
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011 Jan; 16(1):67-74.
Score: 0.007
-
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011 Jan 20; 117(3):780-7.
Score: 0.007
-
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol. 2010 Oct; 47(4):362-70.
Score: 0.007
-
Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood. 2010 Jan 14; 115(2):306-14.
Score: 0.007
-
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009 Sep; 8(9):2509-16.
Score: 0.007
-
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008 Apr 01; 111(7):3742-50.
Score: 0.006
-
Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma. 2007 Apr; 48(4):774-85.
Score: 0.006
-
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006 Oct; 5(19):2223-9.
Score: 0.005
-
Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15; 108(2):630-7.
Score: 0.005
-
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006 Feb 15; 107(4):1555-63.
Score: 0.005
-
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005 May 15; 105(10):4043-50.
Score: 0.005
-
Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation. Int J Biol Macromol. 2025 Jan; 286:138305.
Score: 0.005
-
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024 Oct; 38(10):2073-2084.
Score: 0.005
-
TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma. 2024 Oct; 65(10):1511-1515.
Score: 0.005
-
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Aug 01; 130(15):2652-2659.
Score: 0.005
-
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia. 2024 Apr; 38(4):729-740.
Score: 0.004
-
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023 12; 9(48):eadh1436.
Score: 0.004
-
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. Nat Commun. 2023 09 19; 14(1):5709.
Score: 0.004
-
Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle. 2003 Sep-Oct; 2(5):488-93.
Score: 0.004
-
Bcl-2 inhibition combined with PPARa activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia. Cell Death Dis. 2023 08 29; 14(8):573.
Score: 0.004
-
Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 2003 Dec 01; 102(12):4179-86.
Score: 0.004
-
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Discov. 2023 07 07; 13(7):1656-1677.
Score: 0.004
-
Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia. Cells. 2023 04 11; 12(8).
Score: 0.004
-
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
Score: 0.004
-
Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. Clin Lymphoma Myeloma Leuk. 2022 09; 22(9):652-658.
Score: 0.004
-
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
Score: 0.004
-
Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. J Transl Med. 2021 03 21; 19(1):117.
Score: 0.004
-
Loss of expression of both miR-15/16 loci in CML transition to blast crisis. Proc Natl Acad Sci U S A. 2021 03 16; 118(11).
Score: 0.004
-
Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis. 2020 07 22; 11(7):555.
Score: 0.004
-
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother. 2020 Sep; 129:110390.
Score: 0.003
-
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 11 26; 3(22):3661-3673.
Score: 0.003
-
Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation. Bone Marrow Transplant. 2020 04; 55(4):740-748.
Score: 0.003
-
SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol. 2019 04; 185(2):219-231.
Score: 0.003
-
Glioblastoma and acute myeloid leukemia: malignancies with striking similarities. J Neurooncol. 2018 Jan; 136(2):223-231.
Score: 0.003
-
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. J Hematol Oncol. 2016 11 25; 9(1):129.
Score: 0.003
-
miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. Cell Death Dis. 2016 09 22; 7(9):e2371.
Score: 0.003
-
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 2015 Oct 20; 6(32):33612-22.
Score: 0.003
-
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget. 2014 Oct 15; 5(19):9118-32.
Score: 0.002
-
Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014 May; 73(5):961-74.
Score: 0.002
-
XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opin Investig Drugs. 2013 May; 22(5):663-70.
Score: 0.002
-
Regulation of mRNA stability and its relevance to disease. Lab Invest. 1991 Dec; 65(6):610-21.
Score: 0.002
-
Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 2010 Nov 01; 116(21):4980-90.
Score: 0.002
-
Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res. 2010; 145:197-217.
Score: 0.002
-
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009 Oct 01; 27(28):4741-6.
Score: 0.002
-
Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther. 2008 May; 16(5):886-92.
Score: 0.001
-
Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):852-9.
Score: 0.001
-
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007 Mar 01; 109(5):2121-9.
Score: 0.001
-
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 2006 Aug 02; 98(15):1068-77.
Score: 0.001
-
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4.
Score: 0.001